Prevention & lipidsCross-sectional study
Eligibility for lipid-lowering therapy when applying systemic coronary risk estimation 2 according to guidelines on apparently healthy middle-aged individuals
- Cross-sectional study
- population-based
- random invitation
Authors' conclusion
Nearly all apparently healthy individuals with high and very high CVD risk, or 35% of the total population, were eligible for LLT according to guidelines, and a large proportion had no signs of atherosclerosis. Compared with the SCORE2 equation, the SCORE2 chart resulted in more individuals being eligible for LLT.
Study context
- Population
- Apparently healthy individuals aged 50–64 years in the Swedish Cardiopulmonary Bioimage Study (no previous atherosclerotic cardiovascular disease (CVD), DM or CKD)apparently healthy, of 30,154
- Participants
- 26,570 individuals
- Exposure
- SCORE2 equation vs SCORE2 chart for lipid-lowering therapy (LLT) eligibility
- Outcome
- Proportion eligible for LLT according to the 2021 ESC CVD prevention guidelines
Main finding
As reported in the abstract
Eligibility for LLT (2021 ESC CVD prevention guidelines)
- High 10-year CVD risk, SCORE2 equation
- 32%
- Very high 10-year CVD risk, SCORE2 equation
- 4%
- LDL-C above guideline goals among high- and very-high-risk individuals
- 99%
- Total population eligible for LLT, SCORE2 equation
- 35%
- No signs of coronary atherosclerosis on coronary computed tomography angiography (CCTA) among those eligible (SCORE2 equation) undergoing imaging
- 38%
- Population eligible for LLT, SCORE2 chart
- 52%
- No signs of coronary atherosclerosis among those eligible, SCORE2 chart
- 44%
Observational data: associations, not effects.
Further findings
LLT use in high or very high risk
- Ongoing LLT
- 7%
- Received LLT within 6 months after study participation
- 11%
Original publication
Eligibility for lipid-lowering therapy when applying systemic coronary risk estimation 2 according to guidelines on apparently healthy middle-aged individuals. Eur J Prev Cardiol. Published 6 June 2024. doi:10.1093/eurjpc/zwae190
Summarised from the published abstract; every number is checked against it